Immune Modulators and IVF
- Conditions
- In Vitro Fertilization
- Registration Number
- NCT02626702
- Lead Sponsor
- Weill Medical College of Cornell University
- Brief Summary
Exploring the immune mediators of early pregnancy prospectively may help to identify new early interventions that will increase the likelihood of success and help women make informed decisions regarding their pregnancies.
- Detailed Description
Sera will be obtained from 500 women undergoing IVF at five time periods: cycle Day 2, post HCG, Day 24, Day 28, and/or Day 35.Aliquots of sera will be tested by commercial ELISA kits for concentrations of immune modulators suggestive to be predictive of IVF outcome, such as cytokines (interleukins, tumor necrosis factor, and interferon), neurotrophins (BDNF), protease inhibitors (HE4) and insulin-like growth factors (IGF-1, IGF-2, IGFBP). The results will be correlated with IVF outcomes.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 500
- All fresh transfers
- PGD
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To explore the relationship between immune mediators and IVF outcome prospectively in women who receive in vitro fertilization treatment. 35 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine
🇺🇸New York, New York, United States